Form 8-K · Current report
Merck & Co. 8-K, filed Oct 29, 2026
- Filed
- CIK
- 0000310158
- Accession no.
- 0001104659-26-119825
Summary
Merck & Co. reported third-quarter 2026 worldwide sales of $18.1 billion, up 5%, with GAAP EPS of $2.04 and non-GAAP EPS of $2.49, and narrowed and raised the midpoint of its full-year 2026 sales and non-GAAP EPS guidance. The company highlighted pipeline milestones including Phase 3 data for sac-TMT in advanced or recurrent endometrial cancer, for which the FDA accepted a biologics license application for priority review, and for intismeran autogene plus KEYTRUDA in resected stage IIB-IV melanoma, in collaboration with Moderna.
Key points
- Merck & Co. reported third-quarter 2026 worldwide sales of $18.1 billion, up 5% (4% ex-FX), with KEYTRUDA/KEYTRUDA QLEX sales of $8.6 billion and WINREVAIR sales of $694 million, up 93%.
- GAAP EPS was $2.04 and non-GAAP EPS was $2.49, both including a one-time charge of $0.12 per share tied to a global license agreement with SciBrunch Therapeutics.
- Merck narrowed and raised the midpoint of its full-year 2026 outlook to sales of $66.8–67.3 billion and non-GAAP EPS of $2.77–2.82.
- Chairman and CEO Robert M. Davis said the ESMO oncology data, including the first Phase 3 validation of a therapeutic cancer vaccine, further de-risk the late-phase pipeline.
Written by an AI model from the filing text. It can be incomplete or wrong; the filing on SEC.gov is the record.
Items reported
- 2.02Results of Operations and Financial Condition
- 9.01Financial Statements and Exhibits
From the filing
Item 2.02. Results of Operations and Financial Condition. The following information, including the exhibits hereto, is being furnished pursuant to this Item 2.02. Incorporated by reference is a press release issued by Merck & Co., Inc. on October 29, 2026, regarding earnings for the third quarter of 2026, attached as Exhibit 99.1. Also incorporated by reference is certain supplemental information not included in the press release, attached as Exhibit 99.2. …
An excerpt of the text as filed with the SEC, cut for length.
Readster writes AI-generated summaries of public filings for research purposes only. Summaries can be incomplete or wrong — check the original filing on SEC.gov before relying on it. Nothing here is investment, legal or medical advice.